Clinical Trial Update: Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing once-weekly NNC0195-0092 to daily Norditropin (somatropin) in treatment-naïve prepubertal children with growth hormone deficiency has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency in Children
• Growth Hormone Disorder

Drugs mentioned

• NNC0195-0092 (long-acting pegylated growth hormone)
• Norditropin FlexPro (somatropin)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 2 | Status: COMPLETED | Results posted: 2026-01-16